Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03870802
Other study ID # MACSSI (ET18-150)
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 22, 2021
Est. completion date November 15, 2024

Study information

Verified date January 2024
Source Centre Leon Berard
Contact DELAY Emmanuel, MD
Phone +33 4.78.78.51.29
Email emmanuel.delay@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Monocentric, observational and prospective study in adult women having an early-stage breast cancer without genetic risk. The main objective is to characterize quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland in women: - With a moderate risk of breast cancer progression (women with an early "Luminal A" tumor) = Group A. - With a high risk of breast cancer progression (women with an early "Luminal B" or basal tumor) = Group B.


Description:

Breast cancer is one of the most frequent and the second cause of mortality for women in the world. Breast is a complex organ which has several changes (puberty, pregnancy and menopause). These modifications are controlled by numerous signals as those transmitted by the oestrogens. They are possible through the presence of stem cells in the mammary gland which are able to reply to these signals and can be the target of alterations leading to cancer cells occurence. Breast tumors are composed of complex entities of different kinds of cancer and normal cells which constitute the tumor micro-environment including the immune system cells. This micro-environment transmits a lot of signals to cancer cells and particularly stem cells which can contribute to their survival, the tumor progression and interfere with the treatments efficacy. The detection of the major deregulation of BMP2 synthesis by mammary micro-environment cells may be a reliable and early biomarker of carcinogens exposure and an indicator of a high risk of developing a luminal type breast cancer. The immune micro-environment, which has an impact on solid cancer patients' survival, should be taken into consideration for new therapeutic strategies. Some infiltrating tumour immune cells, as macrophages (TAM) or regulating T and B cells, have shown their key role in tumour escape and metastases apparition. It is relevant to associate the evaluation of immune infiltrate to the breast stem cells in early stage tumours since the literature suggests a functional interaction of these two cellular compartments, particularly in the glioblastoma and the prostate cancer. It seems that mammary stem cells are a major element in the comprehension of breast carcinogenesis but also in the possibilities of repairing the mammary tissue controlling the mammary carcinogenesis. It is fundamental to clarify the role of stem cells and immunity. Our hypothesis is that breast stem cells are altered in women having a high risk of cancer progression. They would be responsible for a reduced activity of cellular repair and/or contribute to tumour development. MACSSI project consists in isolating, quantifying and characterizing the breast stem cells and the isolated immune cells of samples obtained for the prophylactic mastectomy in women presenting different tumour progression risks. The results will be compared to normal samples already collected in women who had a breast reduction.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date November 15, 2024
Est. primary completion date February 22, 2024
Accepts healthy volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Patient requiring a breast surgery (total mastectomy) of an early stage tumour classified as : - Luminal A (Arm A) : Patients with a moderate risk of breast cancer progression or, - Luminal B or Basal (Arm B) : Patients with a high risk of breast cancer progression - Systemic treatment not initiated - Breast cup size = C - Informed and signed consent. Exclusion Criteria: - Neo-adjuvant chemotherapy or hormonotherapy - History of breast irradiation - Pregnant or breastfeeding woman - Patient under tutorship or curatorship - Patient who underwent a lumpectomy with a level-2 oncoplastic surgery (ex: breast reduction with an inverted-T remodeling) - Any other prior anti-tumor treatment - Other medical pathology which may interfere with the biologic evaluation, especially chronic auto-immune diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Characterization of breast stem & immune system cells infiltrated in the mammary gland
Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.

Locations

Country Name City State
France Centre Léon Bérard Lyon

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To characterise quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland according to the risk of breast cancer progression (group A and B) Rate of stem and immune cells and phenotype analysis Within one month after inclusion (date of surgery)
Secondary Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B Functional test: mammosphere Within one month after inclusion (date of surgery)
Secondary Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B Functional test: TDLU Within one month after inclusion (date of surgery)
Secondary Functional characterization, after solitary confinement, of stem cells and immune system cells from groups A and B Functional test: E-CFC - FACS Within one month after inclusion (date of surgery)
Secondary Determination of the stem cells role in the cellular regulation and repair activity Functional tests Within one month after inclusion (date of surgery)
Secondary Determination of the efficacy of the immune systems cells found in the samples in the early stage of breast tumorigenesis FACS Within one month after inclusion (date of surgery)
Secondary Evaluation of the role of breast stem and immune cells in the early stage development of a breast cancer: risk or protective factor ? Functional tests: mammosphere, TDLU, E-CFC - FACS Within one month after inclusion (date of surgery)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A